Shares of DIAGENS-B (ASX: 02526) surged more than 13% during the morning trading session. At the time of writing, the stock was up 8.58%, trading at HK$336.6 with a turnover of HK$2.4756 million.
The catalyst for the move was the official launch of the company's latest product, the iMedLoop global medical imaging data platform, at an innovation seminar and product launch event held in Beijing on July 4th.
Platform Launch Details
The launch event centered on key areas including medical imaging data, foundational models for medical imaging, specialized AI applications for specific diseases and medical specialties, clinical collaboration, and industry ecosystem development. This release signifies a significant step forward for the company in advancing the platformization, scalability, and ecosystem development of its medical imaging AI solutions.
Comprehensive Infrastructure
The newly introduced iMedLoop platform is not merely a single AI tool. Instead, it is positioned as a foundational infrastructure designed for the entire lifecycle of medical imaging AI development and application. It covers critical stages such as data governance, expert annotation, model training, model deployment, and clinical application. The platform's goal is to enhance the efficiency of developing medical imaging AI applications and to facilitate the transition of specialized disease models from project-based development to a standardized, scalable, and continuously iterative process.
Advanced Model Capabilities
At the core of the model training aspect, the company has developed the iMedImage® foundational model for medical imaging. This model is described as the world's first trillion-parameter cross-modal large model for medical imaging. It supports 19 different imaging modalities and is reported to cover over 90% of clinical scenarios, thereby overcoming the limitations of traditional single-modal technologies. This foundational model serves as the underlying engine for developing specialized disease-specific models.
Comments